Stockreport

Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) [Yahoo! Finance]

Rani Therapeutics Holdings, Inc. - Class A  (RANI) 
PDF - RT-111 was well-tolerated, with no serious adverse events - - Celltrion has right of first negotiation to acquire worldwide rights to RT-111 following a Phase 1 cli [Read more]